eligibility_summary
Previously untreated CD20+ DLBCL per 2016 WHO (DLBCL NOS GCB/ABC, T/HRL, EBV+, ALK+, HHV8+, high-grade incl. double/triple-hit), measurable disease (Lugano), IPI ≥3, adequate hematologic, liver, kidney function, LVEF ≥50%. Exclude: CHOP contraindication or prior anthracyclines, CNS lymphoma, or other malignancy affecting compliance/interpretation.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT05831865 tests frontline autologous stem cell transplantation (ASCT) in high‑risk DLBCL after chemoimmunotherapy. Interventions: R‑CHOP → ASCT for CR/CMR, PR/PMR patients get Pola‑R‑CHP then ASCT with Pola‑BEAM conditioning. Drugs/mechanisms (type): rituximab (anti‑CD20 monoclonal antibody, B‑cell depletion via ADCC/CDC/apoptosis), cyclophosphamide (alkylator, DNA crosslinks), doxorubicin/hydroxydaunomycin (anthracycline, topoisomerase II inhibition/intercalation), vincristine/Oncovin (vinca alkaloid, microtubule inhibitor), prednisone (glucocorticoid, lymphocyte apoptosis), polatuzumab vedotin (anti‑CD79b antibody‑drug conjugate delivering MMAE, microtubule disruption). Pola‑BEAM adds carmustine (nitrosourea alkylator) or bendamustine (alkylating agent), etoposide (topo II inhibitor), cytarabine (antimetabolite), melphalan (alkylator). Targets/pathways: CD20+ and CD79b+ malignant B cells, microtubules, DNA replication/repair, topoisomerase II, glucocorticoid signaling, ASCT enables myeloablative therapy via stem cell rescue.